BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Acquired by Peregrine Capital Management LLC

Peregrine Capital Management LLC lifted its stake in BioLife Solutions, Inc. (NASDAQ:BLFS - Free Report) by 3.5% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 364,446 shares of the medical equipment provider's stock after purchasing an additional 12,241 shares during the quarter. Peregrine Capital Management LLC owned about 0.77% of BioLife Solutions worth $8,324,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in BLFS. Rhumbline Advisers grew its position in BioLife Solutions by 0.7% in the first quarter. Rhumbline Advisers now owns 83,227 shares of the medical equipment provider's stock worth $1,901,000 after acquiring an additional 566 shares during the period. GAMMA Investing LLC lifted its stake in shares of BioLife Solutions by 18.6% in the 1st quarter. GAMMA Investing LLC now owns 4,223 shares of the medical equipment provider's stock valued at $96,000 after purchasing an additional 663 shares during the last quarter. 1620 Investment Advisors Inc. grew its holdings in shares of BioLife Solutions by 41.7% during the 4th quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider's stock worth $60,000 after purchasing an additional 675 shares during the period. Smartleaf Asset Management LLC grew its holdings in shares of BioLife Solutions by 27.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 4,469 shares of the medical equipment provider's stock worth $117,000 after purchasing an additional 950 shares during the period. Finally, Steward Partners Investment Advisory LLC acquired a new stake in shares of BioLife Solutions during the 4th quarter worth about $26,000. Hedge funds and other institutional investors own 93.24% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BLFS. HC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of BioLife Solutions in a research note on Tuesday, May 13th. Wall Street Zen cut shares of BioLife Solutions from a "hold" rating to a "sell" rating in a research report on Wednesday, May 21st. One research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $31.17.

Insider Buying and Selling at BioLife Solutions

In related news, major shareholder Casdin Partners Master Fund, L sold 1,000,000 shares of BioLife Solutions stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $23.80, for a total value of $23,800,000.00. Following the completion of the transaction, the insider owned 7,707,165 shares in the company, valued at $183,430,527. The trade was a 11.48% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold 1,007,436 shares of company stock worth $23,965,366 in the last 90 days. 2.20% of the stock is currently owned by corporate insiders.

BioLife Solutions Stock Up 2.2%

Shares of BLFS traded up $0.51 during mid-day trading on Thursday, hitting $23.26. 503,412 shares of the company's stock were exchanged, compared to its average volume of 418,756. The stock's 50-day moving average is $22.61 and its 200-day moving average is $24.52. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.74 and a current ratio of 4.73. BioLife Solutions, Inc. has a fifty-two week low of $18.70 and a fifty-two week high of $29.55. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -80.20 and a beta of 1.79.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last released its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative net margin of 11.81% and a negative return on equity of 0.66%. The company had revenue of $23.94 million for the quarter, compared to analyst estimates of $22.22 million. On average, sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.